Skip to Content
Merck
All Photos(4)

Documents

C4710

Sigma-Aldrich

Monoclonal Anti-Cyclin A antibody produced in mouse

clone CY-A1, ascites fluid

Sign Into View Organizational & Contract Pricing
All Photos(4)

About This Item

MDL number:
MFCD00243105
UNSPSC Code:
12352203
NACRES:
NA.41

biological source

mouse

Quality Level

200

conjugate

unconjugated

antibody form

ascites fluid

antibody product type

primary antibodies

clone

CY-A1, monoclonal

mol wt

antigen 60 kDa

contains

15 mM sodium azide

species reactivity

mouse, human, monkey, bovine

technique(s)

immunocytochemistry: suitable
microarray: suitable
western blot: 1:1,000 using a mouse NIH 3T3 cell extract

isotype

IgG2a

UniProt accession no.

P20248

shipped in

dry ice

storage temp.

−20°C

target post-translational modification

unmodified

Gene Information

human ... CCNA2(890)
mouse ... Ccna2(12428)

General description

Cyclin A is a nuclear protein during S phase and it binds both cdk2 and cdc2. The availability of monoclonal antibody reacting specifically with cyclin A enables the subcellular detection and localization of cyclin A and the measurement of relative differences in cyclin A levels as a function of cell cycle phase.

Specificity

The antibody recognizes an epitope present in amino acids 162-433 of bovine cyclin A. No cross-reactivity is detected with other cyclins (cyclin B, D, or E).

Immunogen

recombinant bovine cyclin A.

Application

Monoclonal Anti-Cyclin A antibody produced in mouse is suitable for:
  • immunocytochemistry
  • microarray
  • western blotting at a dilution of 1:1,000 using a mouse NIH 3T3 cell extract

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

recommended

Product No.
Description
Pricing

Storage Class Code

10 - Combustible liquids

WGK

nwg

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Matthew Hoare et al.
Nature cell biology, 18(9), 979-992 (2016-08-16)
Senescence, a persistent form of cell-cycle arrest, is often associated with a diverse secretome, which provides complex functionality for senescent cells within the tissue microenvironment. We show that oncogene-induced senescence is accompanied by a dynamic fluctuation of NOTCH1 activity, which
Qing-Hua Zhang et al.
The Journal of cell biology, 216(10), 3133-3143 (2017-08-19)
Cyclin A2 is a crucial mitotic Cdk regulatory partner that coordinates entry into mitosis and is then destroyed in prometaphase within minutes of nuclear envelope breakdown. The role of cyclin A2 in female meiosis and its dynamics during the transition
J E Dazard et al.
Oncogene, 19(33), 3693-3705 (2000-08-19)
p53 transcription factor is mutated in most skin cell carcinomas and in more than 50% of all human malignancies. One of its transcriptional targets is MDM2, which in turn down-regulates p53. The role of the p53/MDM2 regulatory loop upon genotoxic
Emma L Hesketh et al.
Cell cycle (Georgetown, Tex.), 14(3), 333-341 (2015-02-07)
The minichromosome maintenance complex (MCM2-7) is the putative DNA helicase in eukaryotes, and essential for DNA replication. By applying serial extractions to mammalian cells synchronized by release from quiescence, we reveal dynamic changes to the sub-nuclear compartmentalization of MCM2 as
Chunyan Weng et al.
International journal of oncology, 42(1), 327-337 (2012-11-09)
Androgen deprivation therapy of prostate cancer with estrogens shows significant cardiovascular side-effects. To develop effective prostate cancer therapeutic agent(s) with minimal cardiovascular side-effects, we compared the effects of various estrogen receptor (ER) ligands on the modulation of dihydrotestosterone (DHT) actions
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service